Centessa Pharmaceuticals (CNTA) Change in Accured Expenses (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Change in Accured Expenses of -$9.0 million for Q1 2026, up 69.49% year-over-year from -$5.3 million in Q1 2025, and down 174.25% on a QoQ basis from $12.1 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 7 years of Change in Accured Expenses data on file, last reported at -$9.0 million in Q1 2026.
- Quarterly Change in Accured Expenses rose 69.49% year-over-year to -$9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 101.78% YoY) and the FY2025 annual result came in at -$15.2 million, down 166.82% from the prior year.
- Change in Accured Expenses fell to -$9.0 million in Q1 2026 per CNTA's latest filing, from $12.1 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $32.7 million in Q4 2024 and bottomed at -$29.6 million in Q1 2025.
- The 5-year median for Change in Accured Expenses is $2.0 million (2023), against an average of $235529.4.
- Peak annual rise in Change in Accured Expenses reached 1501.47% in 2024, while the deepest fall reached 2706.12% in 2024.
- Tracing CNTA's Change in Accured Expenses over 5 years: stood at -$4.8 million in 2022, then soared by 142.28% to $2.0 million in 2023, then surged by 1501.47% to $32.7 million in 2024, then tumbled by 62.91% to $12.1 million in 2025, then tumbled by 174.25% to -$9.0 million in 2026.
- Per Business Quant, the three latest CNTA Change in Accured Expenses figures stand at -$9.0 million (Q1 2026), $12.1 million (Q4 2025), and -$689000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | -9.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.02 Mn |
| Mar 31, 2026 | -9.02 Mn |
| Dec 31, 2025 | 12.14 Mn |
| Dec 31, 2025 | 12.14 Mn |
| Sep 30, 2025 | -689,000.00 |
| Sep 30, 2025 | -689,000.00 |
| Jun 30, 2025 | 2.88 Mn |
| Jun 30, 2025 | 2.88 Mn |
| Mar 31, 2025 | -29.55 Mn |
| Mar 31, 2025 | -29.55 Mn |
| Dec 31, 2024 | 32.73 Mn |
| Dec 31, 2024 | 32.73 Mn |
| Sep 30, 2024 | -3.83 Mn |
| Sep 30, 2024 | -3.83 Mn |
| Jun 30, 2024 | 3.28 Mn |
| Jun 30, 2024 | 3.28 Mn |
| Mar 31, 2024 | -9.42 Mn |
| Mar 31, 2024 | -9.42 Mn |
| Dec 31, 2023 | 2.04 Mn |
| Dec 31, 2023 | 2.04 Mn |
| Sep 30, 2023 | 147,000.00 |
| Sep 30, 2023 | 147,000.00 |
| Jun 30, 2023 | 6.78 Mn |
| Jun 30, 2023 | 6.78 Mn |
| Mar 31, 2023 | -9.77 Mn |
| Mar 31, 2023 | -9.77 Mn |
| Dec 31, 2022 | -4.83 Mn |
| Dec 31, 2022 | -4.83 Mn |
| Sep 30, 2022 | 3.14 Mn |
| Sep 30, 2022 | 3.14 Mn |
| Jun 30, 2022 | 5.37 Mn |
| Jun 30, 2022 | 5.37 Mn |
| Mar 31, 2022 | 2.59 Mn |
| Mar 31, 2022 | 2.59 Mn |
| Dec 31, 2021 | 5.33 Mn |
| Dec 31, 2021 | 5.33 Mn |
| Sep 30, 2021 | 2.93 Mn |
| Sep 30, 2021 | 2.93 Mn |
| Jun 30, 2021 | 3.71 Mn |
| Jun 30, 2021 | 3.71 Mn |
| Mar 31, 2021 | 998,000.00 |
| Mar 31, 2021 | 998,000.00 |
| Dec 31, 2020 | 684,000.00 |
| Dec 31, 2020 | 684,000.00 |
| Sep 30, 2020 | -61,000.00 |
| Sep 30, 2020 | -61,000.00 |